Ocular Hemorrhage Possibly the Result of HMG-CoA Reductase Inhibitors

F. W. Fraunfelder

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy.

Original languageEnglish (US)
Pages (from-to)179-182
Number of pages4
JournalJournal of Ocular Pharmacology and Therapeutics
Volume20
Issue number2
DOIs
StatePublished - Apr 2004

Fingerprint

Eye Hemorrhage
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Oxidoreductases
Bleeding Time
United States Food and Drug Administration
Registries
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ocular Hemorrhage Possibly the Result of HMG-CoA Reductase Inhibitors. / Fraunfelder, F. W.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 20, No. 2, 04.2004, p. 179-182.

Research output: Contribution to journalArticle

@article{0246a622df944f7895e52e3d1b1e22fe,
title = "Ocular Hemorrhage Possibly the Result of HMG-CoA Reductase Inhibitors",
abstract = "This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is {"}possibly{"} due to statin therapy.",
author = "Fraunfelder, {F. W.}",
year = "2004",
month = "4",
doi = "10.1089/108076804773710858",
language = "English (US)",
volume = "20",
pages = "179--182",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Ocular Hemorrhage Possibly the Result of HMG-CoA Reductase Inhibitors

AU - Fraunfelder, F. W.

PY - 2004/4

Y1 - 2004/4

N2 - This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy.

AB - This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy.

UR - http://www.scopus.com/inward/record.url?scp=1842527007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842527007&partnerID=8YFLogxK

U2 - 10.1089/108076804773710858

DO - 10.1089/108076804773710858

M3 - Article

VL - 20

SP - 179

EP - 182

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 2

ER -